stockportfolio.pro
Stocks / BMY vs VRTX
BMY vs VRTX
Bristol-Myers Squibb Company and Vertex Pharmaceuticals Incorporated side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Bristol-Myers Squibb Company (BMY) | Vertex Pharmaceuticals Incorporated (VRTX) | |
|---|---|---|
| Market cap | $115.3B | $113.1B |
| Revenue (latest FY) | $48.19B | $12.00B |
| Net income (latest FY) | $7.05B | $3.95B |
| Revenue growth (5y CAGR) | 2.5% | 14.1% |
| Net margin | 14.6% | 32.9% |
| Return on equity | 38.2% | 21.2% |
| P/E ratio | 15.8 | 26.5 |
| Dividend yield | 4.5% | — |
| Profitable years (of last 10) | 8 | 8 |
| Positive free cash flow | Yes | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open BMY — free Open VRTX — freeFrequently asked questions
Which is bigger, BMY or VRTX?
Bristol-Myers Squibb Company is larger by market capitalization — $115.3B versus $113.1B.
Which grows faster, BMY or VRTX?
Over the last five fiscal years, Vertex Pharmaceuticals Incorporated grew revenue faster — 14.1%/yr versus 2.5%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.